跳至主要内容
临床试验/NCT03883334
NCT03883334Unknown4 期

Efecto de la Isoprinosina en Pacientes Con infección Por VIH y Carga Viral Entre > 50 y < 200 Copias/mL de la Unidad de atención de PVV Del Hospital Enrique Garcés en Quito, Ecuador Durante el año 2019.

Universidad San Francisco de Quito1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年2月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
60
试验地点
1
主要终点
Viral load

研究概览

简要总结

Virological failure is a complication of treatment in patients with HIV, and it can be as high as 42% to first line treatment or around 18% in second line treatment. The reasons behind this phenomenon are several, including adherence to treatment (self-patient) or those related to the drugs (kinetics, interactions) and the virus itself (resistance patterns). People living with HIV needs treatment for all their lives, another factor to facilitate virus resistance and poor adherence to treatment. For that reason, it is necessary to look for additional therapeutic options to minimize this problem, and the use of immunomodulatory drugs is an interesting topic now. Among those drugs, isoprinosine hs been reported not only improve the immune response, it also has the capability to inhibit the replication of RNA virus. Then, we propose an open label clinical trial to evaluate the effect of isoprinosine in HIV patients with a virological load between 50 and 200 copies/ml.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years old.
  • Patients with a viral load (RNA of VIH) between > 50 and < 200 copies/mL after 24 weeks of antiviral therapy or after scheme change.
  • Informed consent signature

排除标准

  • Younger than 18 years old.
  • No virologic failure or RNA of VIH > 200 copies/mL.
  • Presence of a serious opportunistic infection.
  • Renal failure (including litiasis) or presence of gout.
  • Pregnancy.

研究组 & 干预措施

Immunomodulator group

Experimental

Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.

干预措施: Metisoprinol (Drug)

结局指标

主要结局

Viral load

时间窗: Change from Baseline viral load at 3 months

Number of viral copies/mL

次要结局

  • CD4+ count(Change from Baseline CD4+ count at 3 months)

研究者

发起方
Universidad San Francisco de Quito
申办方类型
Other
责任方
Principal Investigator
主要研究者

Enrique Teran

Professor

Universidad San Francisco de Quito

研究点 (1)

Loading locations...

相似试验